Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases

–   Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif. , Jan. 8, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company’s 2023 achievements and previewed a number of important milestones expected